COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Covid19
- Sponsor
- Wake Forest University Health Sciences
- Enrollment
- 47
- Locations
- 1
- Primary Endpoint
- COVID-19 incidence and prevalence in the ALS population
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal neurodegenerative disease characterized by progressive weakness involving limb, bulbar, and respiratory muscles.There is currently no information suggesting how COVID-19 affects patients diagnosed with amyotrophic lateral sclerosis (ALS). This is especially important as respiratory compromise is common in ALS patients and can complicate the clinical course as COVID-19 could lead to respiratory failure and need for intubation. We intend that this registry will guide our understanding of how COVID-19 affects patients with ALS.
Detailed Description
The purpose of this registry is to assess the incidence and prevalence of COVID-19 in ALS patients, the effect of COVID-19 on ALS disease trajectory, and the impact, if any, of edaravone, riluzole and other concomitant medication used in ALS like Albuterol and dextromethorphan/quinidine (Nuedexta) on these parameters. COVID-19 incidence and prevalence in the ALS population will be assessed through outcomes reporting ranging from recovered infections to patient death reported in a patient facing registry.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of ALS and
- •A confirmed COVID-19 infection determined by:
- •positive SARS-CoV-2 viral RNA PCR test and/or
- •positive serology antibody testing for SARS-CoV-2
Exclusion Criteria
- •No ALS diagnosis
- •No confirmed COVID-19 infection
Outcomes
Primary Outcomes
COVID-19 incidence and prevalence in the ALS population
Time Frame: Data will be collected through study completion, an average of 3 years
Assessed through outcomes reporting ranging from recovered infections to patient death reported in a patient facing registry.